345 related articles for article (PubMed ID: 20531290)
1. Intestinal FXR-mediated FGF15 production contributes to diurnal control of hepatic bile acid synthesis in mice.
Stroeve JH; Brufau G; Stellaard F; Gonzalez FJ; Staels B; Kuipers F
Lab Invest; 2010 Oct; 90(10):1457-67. PubMed ID: 20531290
[TBL] [Abstract][Full Text] [Related]
2. Differential regulation of bile acid homeostasis by the farnesoid X receptor in liver and intestine.
Kim I; Ahn SH; Inagaki T; Choi M; Ito S; Guo GL; Kliewer SA; Gonzalez FJ
J Lipid Res; 2007 Dec; 48(12):2664-72. PubMed ID: 17720959
[TBL] [Abstract][Full Text] [Related]
3. Enterohepatic circulation of bile salts in farnesoid X receptor-deficient mice: efficient intestinal bile salt absorption in the absence of ileal bile acid-binding protein.
Kok T; Hulzebos CV; Wolters H; Havinga R; Agellon LB; Stellaard F; Shan B; Schwarz M; Kuipers F
J Biol Chem; 2003 Oct; 278(43):41930-7. PubMed ID: 12917447
[TBL] [Abstract][Full Text] [Related]
4. Protective effects of farnesoid X receptor (FXR) on hepatic lipid accumulation are mediated by hepatic FXR and independent of intestinal FGF15 signal.
Schmitt J; Kong B; Stieger B; Tschopp O; Schultze SM; Rau M; Weber A; Müllhaupt B; Guo GL; Geier A
Liver Int; 2015 Apr; 35(4):1133-1144. PubMed ID: 25156247
[TBL] [Abstract][Full Text] [Related]
5. Muricholic bile acids are potent regulators of bile acid synthesis via a positive feedback mechanism.
Hu X; Bonde Y; Eggertsen G; Rudling M
J Intern Med; 2014 Jan; 275(1):27-38. PubMed ID: 24118394
[TBL] [Abstract][Full Text] [Related]
6. Selective activation of nuclear bile acid receptor FXR in the intestine protects mice against cholestasis.
Modica S; Petruzzelli M; Bellafante E; Murzilli S; Salvatore L; Celli N; Di Tullio G; Palasciano G; Moustafa T; Halilbasic E; Trauner M; Moschetta A
Gastroenterology; 2012 Feb; 142(2):355-65.e1-4. PubMed ID: 22057115
[TBL] [Abstract][Full Text] [Related]
7. Effects of essential fatty acid deficiency on enterohepatic circulation of bile salts in mice.
Lukovac S; Los EL; Stellaard F; Rings EH; Verkade HJ
Am J Physiol Gastrointest Liver Physiol; 2009 Sep; 297(3):G520-31. PubMed ID: 19608735
[TBL] [Abstract][Full Text] [Related]
8. Fibroblast Growth Factor 21 Response in a Preclinical Alcohol Model of Acute-on-Chronic Liver Injury.
Christidis G; Karatayli E; Hall RA; Weber SN; Reichert MC; Hohl M; Qiao S; Boehm U; Lütjohann D; Lammert F; Karatayli SC
Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360670
[TBL] [Abstract][Full Text] [Related]
9. Glucagon-like peptide 1 analogue prevents cholesterol gallstone formation by modulating intestinal farnesoid X receptor activity.
Zhang Z; Du Z; Liu Q; Wu T; Tang Q; Zhang J; Huang C; Huang Y; Li R; Li Y; Zhao Y; Zhang G; Zhou J; Huang H; Fang Z; He J
Metabolism; 2021 May; 118():154728. PubMed ID: 33581130
[TBL] [Abstract][Full Text] [Related]
10. Impaired Intestinal Farnesoid X Receptor Signaling in Cystic Fibrosis Mice.
Ikpa PT; Doktorova M; Meijsen KF; Nieuwenhuijze NDA; Verkade HJ; Jonker JW; de Jonge HR; Bijvelds MJC
Cell Mol Gastroenterol Hepatol; 2020; 9(1):47-60. PubMed ID: 31470114
[TBL] [Abstract][Full Text] [Related]
11. FXR agonist GW4064 improves liver and intestinal pathology and alters bile acid metabolism in rats undergoing small intestinal resection.
Cao Y; Xiao Y; Zhou K; Yan J; Wang P; Yan W; Cai W
Am J Physiol Gastrointest Liver Physiol; 2019 Aug; 317(2):G108-G115. PubMed ID: 30920307
[TBL] [Abstract][Full Text] [Related]
12. Differential regulation of bile acid and cholesterol metabolism by the farnesoid X receptor in Ldlr -/- mice versus hamsters.
Gardès C; Chaput E; Staempfli A; Blum D; Richter H; Benson GM
J Lipid Res; 2013 May; 54(5):1283-99. PubMed ID: 23431047
[TBL] [Abstract][Full Text] [Related]
13. Hepatic cholesterol accumulation ascribed to the activation of ileum Fxr-Fgf15 pathway inhibiting hepatic Cyp7a1 in high-fat diet-induced obesity rats.
Duan Y; Zhang F; Yuan W; Wei Y; Wei M; Zhou Y; Yang Y; Chang Y; Wu X
Life Sci; 2019 Sep; 232():116638. PubMed ID: 31288013
[TBL] [Abstract][Full Text] [Related]
14. PPARα-UGT axis activation represses intestinal FXR-FGF15 feedback signalling and exacerbates experimental colitis.
Zhou X; Cao L; Jiang C; Xie Y; Cheng X; Krausz KW; Qi Y; Sun L; Shah YM; Gonzalez FJ; Wang G; Hao H
Nat Commun; 2014 Sep; 5():4573. PubMed ID: 25183423
[TBL] [Abstract][Full Text] [Related]
15. Interaction of glucocorticoids with FXR/FGF19/FGF21-mediated ileum-liver crosstalk.
Al-Aqil FA; Monte MJ; Peleteiro-Vigil A; Briz O; Rosales R; González R; Aranda CJ; Ocón B; Uriarte I; de Medina FS; Martinez-Augustín O; Avila MA; Marín JJG; Romero MR
Biochim Biophys Acta Mol Basis Dis; 2018 Sep; 1864(9 Pt B):2927-2937. PubMed ID: 29883717
[TBL] [Abstract][Full Text] [Related]
16. Mouse organic solute transporter alpha deficiency alters FGF15 expression and bile acid metabolism.
Lan T; Rao A; Haywood J; Kock ND; Dawson PA
J Hepatol; 2012 Aug; 57(2):359-65. PubMed ID: 22542490
[TBL] [Abstract][Full Text] [Related]
17. Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis.
Inagaki T; Choi M; Moschetta A; Peng L; Cummins CL; McDonald JG; Luo G; Jones SA; Goodwin B; Richardson JA; Gerard RD; Repa JJ; Mangelsdorf DJ; Kliewer SA
Cell Metab; 2005 Oct; 2(4):217-25. PubMed ID: 16213224
[TBL] [Abstract][Full Text] [Related]
18. Promotion of liver regeneration/repair by farnesoid X receptor in both liver and intestine in mice.
Zhang L; Wang YD; Chen WD; Wang X; Lou G; Liu N; Lin M; Forman BM; Huang W
Hepatology; 2012 Dec; 56(6):2336-43. PubMed ID: 22711662
[TBL] [Abstract][Full Text] [Related]
19. Mouse species-specific control of hepatocarcinogenesis and metabolism by FGF19/FGF15.
Zhou M; Luo J; Chen M; Yang H; Learned RM; DePaoli AM; Tian H; Ling L
J Hepatol; 2017 Jun; 66(6):1182-1192. PubMed ID: 28189755
[TBL] [Abstract][Full Text] [Related]
20. Cholesterol-lowering effects of taurine through the reduction of ileal FXR signaling due to the alteration of ileal bile acid composition.
Miyata M; Tanaka T; Takahashi K; Funaki A; Sugiura Y
Amino Acids; 2021 Oct; 53(10):1523-1532. PubMed ID: 34596761
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
